Wade T. Iams, MD

Wade Iams, MD, is the director of Lung Cancer Research at Tennessee Oncology in Nashville.

Articles

Multidisciplinary Collaboration to Improve Early Recognition and Care For CA-LEMS

December 12th 2025

Oncologists and neurologists enhance patient care through effective collaboration, early screening, and utilizing specialized resources for cancer-associated conditions.

NCCN Guidelines and Management of CA-LEMS in the Practice

December 12th 2025

Oncologists explore updated NCCN guidelines for diagnosing neurologic paraneoplastic syndromes in small cell lung cancer, emphasizing multidisciplinary care.

Monitoring and Optimizing Treatment Response in LEMS Management

December 12th 2025

Explore effective treatment monitoring strategies for amifampridine, including side effects management and titration techniques for optimal patient care.

Treatment Strategies for CA-LEMS

December 12th 2025

Oncologists explore the challenges of distinguishing between chemotherapy fatigue and cancer-related limb pain, emphasizing the need for effective screening tools.

Understanding CA-LEMS Pathophysiology

December 10th 2025

Panelists discuss how CA-LEMS biology reflects an off-target antitumor immune response (often with SCLC) that generates antibodies against presynaptic VGCCs, reducing acetylcholine release and causing proximal weakness with brief strength improvement after repeated activation.

Clinical Presentation and Early Identification of Cancer-Associated LEMS

December 10th 2025

Panelists discuss how early segment-level recognition of CA-LEMS hinges on spotting hallmark clinical cues (proximal lower-extremity weakness, autonomic dysfunction, and reflexes that transiently improve after exercise) and not dismissing symptoms as deconditioning or cancer-treatment effects, given frequent links to SCLC and other malignancies.

Unmet Needs Research Aims to Address in Early-Stage NSCLC

August 14th 2025

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss ongoing research in early-stage non–small cell lung cancer.

Closing Perspectives: Unmet Needs, Emerging Advances, and the Future of Early-Stage NSCLC Treatment

August 12th 2025

Panelists discuss how future advances will focus on biomarker-driven personalized approaches, platform trials to increase pathologic complete response rates, circulating tumor DNA (ctDNA)-guided therapy escalation and de-escalation, and the critical importance of comprehensive molecular testing in the neoadjuvant setting.

How Immunotherapy Could Continue to Affect Early-Stage NSCLC Management

August 7th 2025

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss how immunotherapy could continue to reshape early NSCLC management.

Factors Influencing Adjuvant Treatment Decisions in Early-Stage NSCLC

August 7th 2025

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss factors that affect adjuvant treatment decisions in early non–small cell lung cancer.

PACIFIC-R 5-Year Follow-Up: Real-World Outcomes and Implications for Unresectable NSCLC Treatment

August 5th 2025

Panelists discuss how the PACIFIC-R real-world data demonstrates excellent long-term outcomes with a median survival of 60 months, validating the durvalumab consolidation approach while addressing management strategies for patients who progress on or after immunotherapy.

Surgical Attrition in Resectable NSCLC: Risk Factors, Patient Communication, and Strategies to Optimize Continuity of Care

August 5th 2025

Panelists discuss how neoadjuvant chemoimmunotherapy maintains acceptable surgical safety profiles with mortality rates under 4% and how technical complexity primarily stems from hilar lymph node involvement rather than the systemic therapy itself, requiring experienced surgeons to handle these cases.

Clinical Utility of ctDNA in Guiding Perioperative Treatment Decisions in Early-Stage NSCLC

July 29th 2025

Panelists discuss how circulating tumor DNA (ctDNA) serves as a promising biomarker for identifying patients at higher risk who may benefit from therapy escalation, though they acknowledge the current lack of prospective data on how to act therapeutically on positive ctDNA results.

Optimizing Adjuvant Therapy Decisions in Resectable NSCLC: Integrating Pathologic Response, PD-L1, and Nodal Status

July 29th 2025

Panelists discuss how treatment decisions should integrate multiple factors, including pathologic complete response (pCR), PD-L1 status, and nodal involvement, with particular emphasis on continuing adjuvant therapy for N2 disease and non-PCR patients despite the complexity of using residual viable tumor as a decision-making tool.

Updated Findings From CheckMate-816 for Neoadjuvant Nivolumab Plus Chemo in Resectable NSCLC

July 24th 2025

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss updated findings for neoadjuvant nivolumab plus chemotherapy in resectable NSCLC.

Surgical Outcomes From CheckMate-77T With Perioperative Nivolumab in Resectable NSCLC

July 24th 2025

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss surgical outcomes from CheckMate-77T for perioperative nivolumab in resectable NSCLC.

FDA Green-Lights Subcutaneous Nivolumab: What It Means for Early-Stage NSCLC Care

July 22nd 2025

Panelists discuss how subcutaneous (SQ) nivolumab administration offers patient convenience and potential logistical advantages, particularly in the maintenance setting, though they acknowledge limited current adoption and need for more biological data on efficacy differences.

MDT Management of Borderline Resectable Early-Stage NSCLC and Delayed Surgery After Neoadjuvant IO

July 22nd 2025

Panelists discuss how borderline resectable patients can be made resectable through neoadjuvant chemoimmunotherapy when surgeons have clear, objective goals for what they aim to achieve rather than vague hopes to make surgery “less scary.”

Perioperative Nivolumab in Resectable NSCLC: Updated Data From CheckMate-77T

July 17th 2025

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss updated data from CheckMate-77T of perioperative nivolumab in resectable NSCLC.

How Immunotherapy Is Affecting Perioperative Treatment Decisions in Early-Stage NSCLC

July 17th 2025

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss how immunotherapy is affecting perioperative treatment in early-stage non–small cell lung cancer.